GW1516, (also known as GW501516, Cardarine and Endurobol) was originally developed in the 1990s as a treatment for diabetes, obesity and cardiovascular disease.

It was discontinued in 2007, after it was linked to the rapid development of cancer during trials on mice.

After a number of positive tests for GW1516 in 2013, WADA released a warning on the health risks of GW1516.

In June 2018, the Australian Therapeutic Goods Administration (TGA) included GW1516 in the Poisons Standard under Schedule 10.


No violations found.